<DOC>
	<DOCNO>NCT02391623</DOCNO>
	<brief_summary>PF-06427878 new compound propose treatment hyperlipidemia . The primary purpose study evaluate safety , tolerability , pharmacokinetics multiple oral dos PF-06427878 healthy adult subject .</brief_summary>
	<brief_title>A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject non childbearing potential . Body Mass Index ( BMI ) 17.5 35.4 kg/m2 ; total body weight &gt; 50 kg Subjects fast TG level &gt; =90 mg/dL &lt; =500 mg/dL follow overnight fast Subjects low density lipoprotein cholesterol 115 mg/dL 190 mg/dL follow overnight fast â€¢Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple Ascending Dose</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>